Catalyst Biosciences YTD Return
The CBIO YTD return is 53.37% with dividends reinvested through 06/15/2026. Investors often use YTD return to compare year-to-date performance across securities because current calendar year return information is important for tax planning.
This page shows CBIO YTD return, annualized return, start and end dates, and the growth of a hypothetical $10,000 investment with dividends reinvested.
| CBIO YTD Return Table | ||||||||||||||||||||||||||||||
CBIO YTD return is presented with the assumption of reinvestments of any dividends on ex-date. |
| YTD Return Benchmarks |
|
Compare CBIO YTD return (see YTD Return Formula;
YTD Return vs Yield) versus benchmarks: YTD Return on S&P YTD Return on Dow YTD Return on Nasdaq 100 YTD Return on Russell 2000 YTD Return on Gold YTD Return on 10 Year Treasury |
| CBIO Share Performance |
| CBIO YTD Return Chart | |||
Also see: CBIO Average Annual Return | |||
| About Crescent Biopharma Inc (New) |
| GlycoMimetics, Inc. is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and for inflammatory diseases. It is developing a pipeline of glycomimetics, which are small molecules that mimic the structure of carbohydrates involved in biological processes, to inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer and infection. Its drug candidates include Uproleselan, GMI-1687, Galectin Antagonists and GMI-1359. The CBIO YTD return is shown above.
The YTD Return on the CBIO YTD return page and across the coverage universe of our site, is a measure of the total return for a given investment year-to-date for the current calendar year (up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely useful in the context of our country's tax system which taxes gains and income on a calendar year basis. Thus, researching Year-To-Date Returns is good practice for investors — whether CBIO YTD return or other benchmarks/peers — and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors by performing the CBIO YTD return calculation (with any dividends reinvested as applicable), and to provide a coverage universe of many stocks and ETFs to be able to compare YTD returns. |
| CBIO Current Stock Quote |
Quotes delayed 20 minutes  Free CBIO Email Alerts:
Get Dividend Alerts 
Get SEC Filing Alerts
|
| Video: Don't Forget Dividends in YTD Return! | |
|
| YTD Return Peers |
| Catalyst Biosciences (CBIO) is categorized under the Healthcare sector; to help you further research YTD return performance across stocks, below are some other companies in the same sector:
CBLI YTD Return CBM YTD Return CBMG YTD Return CBPO YTD Return CBUS YTD Return CCCC YTD Return CCEL YTD Return CCRN YTD Return CCXI YTD Return CDAK YTD Return More Healthcare companies » |
Click the button below for your complimentary copy of Your Early Retirement Portfolio: Dividends Up to 8.2%—Every Month—Forever.
You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 8.2%.
Video: Don't Forget Dividends in YTD Return!